Detailed Narrative
Q4 FY25 Performance and Macro Dynamics
BD reported Q4 FY25 revenue of $5.9 billion, up 7% reported and 3.9% organic, with New BD organic growth accelerating to 4.9%. Full-year revenue reached a record $21.8 billion, up 7.7% reported and 2.9% organic. Adjusted diluted EPS for Q4 was $3.96, contributing to a record $14.40 for the full year, representing 9.6% growth despite a 2-point tariff impact🌐. The company navigated greater-than-anticipated impacts from reduced Pharm Systems vaccine demand and subdued Biosciences academic/government research funding, though Diagnostic Solutions returned to positive growth.
Strategic Actions for New BD and Commercial Excellence
To accelerate its strategy, BD is re-architecting its operating model to create a more focused, agile vertical organization with commercial teams aligned to business units. The company is investing an incremental $30 million to expand its sales force in targeted high-growth markets, including a 15% increase in both PI and APM sales forces. Michael Feld's role has been expanded to Chief Revenue Officer to drive commercial excellence, aiming for best-in-class performance.
Fueling Innovation and Cost Optimization
BD is reallocating nearly $50 million of corporate costs into R&D and businesses to fuel innovation in high-growth markets like tissue regeneration, PureWick adjacent markets, Biologic Drug Delivery, and Connected Care. This includes investments behind new product launches such as the BD Incada AI-enabled platform, BD Pyxis Pro, and the recently 510(k) cleared HemoSphere Stream. Additionally, the company initiated a 2-year, $200 million cost-out program, with approximately half expected in FY26, to address stranded corporate costs.
Waters Transaction and Long-term Value Creation
The separation of Biosciences and Diagnostic Systems with Waters remains on track, with FTC clearance received and an expected close around the end of Q1 calendar year 2026. This transaction is viewed as a significant strategic and financial opportunity to unlock value, with the New BD focusing on its pure-play MedTech profile, deep innovation pipeline, and over 90% consumables revenue. The company anticipates New BD's pro forma adjusted EPS growth to be over 200 basis points higher than WholeCo post-transaction.
BD Excellence and Capital Allocation Strategy
BD Excellence continues to drive strong P&L leverage, with FY25 adjusted gross margin up 140 basis points and operating margin up 80 basis points. The company achieved record consumables quality with a 50% reduction in manufacturing nonconformances and over 8% gross productivity improvements in plants. The enhanced capital allocation strategy prioritizes internal investment, share repurchases (including an incremental $250 million this quarter and at least half of the $4 billion Waters proceeds), and a reliable, increasing dividend, aiming for steadily increasing ROIC.
FY26 Guidance and Phasing
The FY26 guidance reflects a prudent approach, incorporating headwinds from Alaris capital installations (>100 bps impact), China VBP (mid-teens decline, 100 bps impact), and Pharm Systems vaccine demand (~25% decline, 50 bps impact). Despite these, the remaining 90% of the portfolio is expected to grow mid-single digits. Q1 FY26 revenue is projected to be down low single digits, with adjusted diluted EPS in the range of $2.75 to $2.85, due to these factors and tough prior-year comparisons, with growth expected to step up in Q2 and Q3.